Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Gilead's CEO Says New Hepatitis C Drug Attracts Payers

Gilead Sciences Inc. (GILD:US), the world’s largest maker of HIV medicines, said insurers have responded favorably over coverage of its new hepatitis C drug, which has a price tag of $84,000 for a 12-week course of treatment.

Published
13 February 2014
From
Bloomberg Businessweek
Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C

The data submitted in the NDA support the use of LDV/SOF in patients with genotype 1 hepatitis C virus (HCV) infection, with a treatment duration of eight or 12 weeks depending on prior treatment history and whether they have cirrhosis. Approximately 75 percent of people infected with HCV in the United States have the genotype 1 strain of the virus.

Published
11 February 2014
From
Gilead press release
New hepatitis C pill lifts Gilead's 4Q sales

Gilead Sciences said Tuesday that sales of its hepatitis C pill Sovaldi totaled $139.4 million after the drug was approved in December, helping its fourth-quarter profit rise 4 percent.

Published
07 February 2014
From
Bloomberg Businessweek
Gilead to license hepatitis C drug to lower-cost manufacturers in India

Gilead Sciences plans to license its breakthrough hepatitis C drug Sovaldi to a number of Indian generic pharmaceutical manufacturers, allowing for lower-priced sales of the medication in that developing nation, according to the company.

Published
06 February 2014
From
Reuters
Gilead, local generic players in talks to bring hepatitis C drug into India

California-based drug-maker Gilead Sciences Inc is in discussions with a handful of local pharmaceutical companies to bring its much anticipated oral Hepatitis C drug Sovaldi (sofosbuvir) into India.

Published
04 February 2014
From
The Hindu
Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences

The hepatitis C drug-marketing battle is heating up. Both the Abbvie and Gilead hepatitis C regimens are equally effective, with SVR (cure) rates in the high 90% range for both treatment naive and experienced patients. That means the choice for doctors and patients will likely come down to convenience and price.

Published
03 February 2014
From
The Street
AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1

AbbVie has completed phase III studies of its interferon-free three-drug regimen and reports SVR(12) rates above 90% in all patients groups studied, including 92%-96% SVR(12) rates in patients with compensated cirrhosis. AbbVie expects a 2014 US launch.

Published
31 January 2014
From
AbbVie press release
US medical societies launch new hepatitis C treatment guidelines

The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first

Published
30 January 2014
By
Liz Highleyman
At $84000 Gilead Hepatitis C Drug Sets Off Payer Revolt

Gilead’s new drug, Sovaldi, costs $84,000 for a 12-week treatment. Such breakthrough treatments and their stratospheric price tags have “absolutely” caused insurers to reconsider covering high-priced hepatitis, diabetes and other treatments, said Sumit Dutta, chief medical officer of Catamaran, the fourth-biggest U.S. pharmacy benefit manager, or PBM.

Published
27 January 2014
From
Bloomberg
Only just the beginning of the end of hepatitis C

The main drawback of these new agents is the huge price tag, which will make treatment out of reach for people in the developed and developing world. The other concern is the limited testing of these new treatments on less common genotypes and marginalised populations disproportionately affected by HCV infection. For example, there has been minimal testing among those co-infected with HIV.

Published
26 January 2014
From
The Lancet (editorial)

Filter by country